• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

My Top Six 2020 Stock Picks Gained an Average of 75%

A few of these names continue to look good in 2021.
By JAMES "REV SHARK" DEPORRE
Dec 30, 2020 | 11:08 AM EST
Stocks quotes in this article: AUPH, PSNL, TPX, REPH, DDOG, INMD, ARKG

Back in early 2020, I picked six stocks that I thought would perform well in 2020. The six names were Aurinia Pharmaceuticals (AUPH) , Personalis (PSNL) , Tempur Sealy (TPX) , Recro Pharmaceuticals (REPH) , Datadog (DDOG) , and InMode (INMD) .

If I had foreseen a pandemic I probably would have changed some of my picks but overall they did quite well with an average gain of 75%. I still like AUPH, PSNL, and INMD in the year ahead. Here is how they have performed:

PSNL up 273%. This was a name that had a great story in the cancer genomic testing area but went unrecognized for a long time. It was finally discovered and jumped in the last few months due in part to aggressive buying by the ARK Genomic Revolution Multi-Sector ETF (ARKG) . It is still a great story and probably a potential acquisition play but it's no longer cheap and will need to perform well to keep running

DDOG up 166%. DDOG is a cloud play that benefited from the 'work at home' theme this year. The company assists in monitoring the operation of software and provides analytics. It has had tremendous revenue growth but it is very expensive and will need to continue to put up big numbers. I would buy this only after a deeper pullback.

TPX up 27%. TPX took a big hit as retail sales of bedding products dropped sharply when the Covid crisis hit but it recovered very well. Sales grew 38% in the third quarter and it still looks relatively cheap. This is not a momentum name but should be solid stock in the year ahead.

INMD up 21%. INMD provides devices for minimally-invasive aesthetic procedures. Its business dropped sharply but is roaring back with strong eps and revenue in the third quarter and predicted eps growth of 25% in 2021. I believe this business still has substantial upside and should see some good gains in 2021.

AUPH down 30%. AUPH is a classic example of a stock with good news but not yet appreciated by the market. It made substantial progress in the development of its drug for the treatment of lupus nephritis but the market is waiting for FDA approval which is expected in late January. I believe this stock will see increased interest as the FDA decision approaches.

REPH down 84%. The big loser was REPH which is a contract manufacturer of pharmaceuticals. My view was that there was an increased focus on shifting drug manufacturing to the U.S. but management simply failed to perform. The stock has recently recovered but still has much to prove before I'd be interested again.

The most important lesson from these picks is that it is good to have some diversification. The winners more than offset the two losers.

I'll have some new picks for 2021 coming soon.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, James "Rev Shark" DePorre was Long PSNL, AUPH, INMD.

TAGS: Economy | Investing | Markets | Stocks | Trading | Coronavirus

More from Investing

The Psilocybin Patent Race Is On

Debra Borchardt
Mar 6, 2021 12:30 PM EST

It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.

The Challenge of Short Selling

James "Rev Shark" DePorre
Mar 6, 2021 10:00 AM EST

Short selling is a powerful tool, but it is not just the inverse of going long and requires a very different mindset to do it effectively.

Kass: There Are Many Reasons to Be a Bear

Doug Kass
Mar 6, 2021 8:15 AM EST

I believe the markets are headed lower - probably not in a straight line or as steep as the last few days, but in a saw tooth fashion lower.

Bounce Takes Some of the Sting Out of a Painful Week

James "Rev Shark" DePorre
Mar 5, 2021 4:51 PM EST

It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.

The Selloff in Twilio Could Extend Deeper Into March

Bruce Kamich
Mar 5, 2021 2:30 PM EST

TWLO could bounce in the short-run but avoid the long side for now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login